Global Brain Tumor Therapeutics Market Trends, Size, By Type of Brain Cancer (Glioblastoma, Meningioma, Pituitary Tumors, and Other Types of Brain Cancer), By Therapy (Chemotherapy, Immunotherapy, Gene Therapy, and Other Therapies), By Region (North Ameri

Global Brain Tumor Therapeutics Market Trends, Size, By Type of Brain Cancer (Glioblastoma, Meningioma, Pituitary Tumors, and Other Types of Brain Cancer), By Therapy (Chemotherapy, Immunotherapy, Gene Therapy, and Other Therapies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa): Global Opportunity Analysis and Industry Forecast, 2023-2030.

Global Brain Tumor Therapeutics Market

The Global Brain Tumor Therapeutics Market was valued at US$ 1.92 Bn in 2022, estimated to reach US$ 2.90 Bn by 2030, with a CAGR of 4.68% from 2023-2030.

Brain tumors are formed when brain cells begin to grow uncontrolled. The brain tissue in this syndrome develops cancerous cells. A tumor is created as cancer cells multiply and obstruct the brain's ability to control sensation, motor movement, memory, and other crucial processes. Primary brain tumors are those in which the cancer cells originate in the brain tissue; secondary or metastatic brain tumors are those in which the cancer cells have spread to the brain from other parts of the body. The size, nature, and location of the tumor, together with any symptoms, general health, and therapeutic preferences, will all influence the course of treatment for a brain tumor. Your care team may include physician assistants, oncology nurses, nurse practitioners, pharmacists, counselors, dietitians, specialists, and other medical professionals.

Market Drivers

The market for cancer diagnostics is expected to develop as a result of rising brain tumor cases and considerable diagnostic breakthroughs. With the development of insulin treatments, the viability of peptide-based therapeutics became apparent to the medical care industry, and the market for disease therapeutics was already familiar with peptide-based drug delivery.

Combining peptide-based drugs with chemotherapy has emerged as a promising strategy for furthering the market development of disease therapeutics. The execution of peptide medications and peptide therapeutics in the malignant tumor diagnosis and therapeutics scene has developed dramatically in recent years. Partners in the market for medicines and diagnosis for malignant brain tumors are promoting research into innovative delivery systems.

Market Restraints

The expansion of the brain tumor diagnosis and therapeutics market is anticipated to be hampered during the forecast period by rising illness treatment and therapeutics costs as well as the side effects of brain therapies.

Market Segmentation

The scope of the Global Brain Tumor Therapeutics Market covers segmentation based on Product Consulting Type of Brain Cancer, Therapy, and Region.

Based on Type of Brain Cancer, the market is segmented into Glioblastoma, Meningioma, Pituitary Tumors, and Other Types of Brain Cancer.

Based on Therapy, the market is classified into Chemotherapy, Immunotherapy, Gene Therapy, and Other Therapies.

Regional Analysis

The Global Brain Tumor Therapeutics Market is segmented into 5 main regions, namely North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

North America is expected to account for a sizeable portion market during the forecast period. The sophisticated healthcare sector in the United States, along with the population's growing awareness of advanced technologies, are factors that are expected to make this country the market leader. The American Brain Tumour Association reports that in 2021, more than 84,000 people received a primary brain tumor diagnosis, and roughly 18,000 of those people passed away as a result of a primary malignant brain tumor. The same source also claims that in 2021, there will be more than 28,000 pediatric brain tumor diagnoses in the US. It is anticipated that the increased incidence of brain tumors would propel the development of this area.

Key Developments

In April 2021, MindMed and Nextage Therapeutics agreed to a Memorandum of Understanding (the "MOU") that makes use of Nextage's unique Brain Targeting Liposome System (BTLS) delivery technology to optimize the administration of particular psychedelic drug candidates.

A definitive merger agreement between Roche and GenMark Diagnostics was signed in March 2021, allowing Roche to entirely purchase GenMark for USD 24.05 per share in an all-cash deal.

Key Players

Pfizer Inc., Mayo Foundation for Medical Education and Research (MFMER)., GENERAL ELECTRIC COMPANY, AstraZeneca, Merck & Co., Inc., Siemens Healthcare Private Limited, Carestream Health., Hitachi, Ltd., Koninklijke Philips N.V., Shimadzu Corporation, CANON MEDICAL SYSTEMS CORPORATION, Eisai Co., Ltd., Elekta AB.

Market Taxonomy

By Type of Brain Cancer

• Glioblastoma
• Meningioma
• Pituitary Tumors
• Other Types of Brain Cancer

• Chemotherapy
• Immunotherapy
• Gene Therapy
• Other Therapies

• North America
• U.S.
• Canada
• Mexico
• Latin America
• Brazil
• Argentina
• Colombia
• Peru
• Chile
• Venezuela
• Rest of Latin America
• Europe
• Germany
• France
• UK
• Russia
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• New Zealand
• Singapore
• Malaysia
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest Middle East & Africa

• What are the Key Opportunities in Global Bonsai Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have the highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?